05/11/2026
Are you a physician interested in anti-aging medicine or wellness therapies? Are you considering using peptides now or in the future? Well, if you had asked me 2 weeks ago, I would have been worried for you. But the regulatory landscape for BPC-157 just shifted.
For many compounding pharmacies and physicians, it’s no longer on the "naughty list," signaling a green light for compounding to resume.
However, as an FDA regulatory attorney, I’m seeing a dangerous trend: patients bypassing the clinic to buy "research only" vials online.
If you are a physician contemplating integrating BPC-157 into your protocols, here is what you need to know to stay on the right side of the law:
1. Physician Oversight is Mandatory: The removal of certain restrictions doesn't create a "wild west" scenario. A valid patient-provider relationship and a specific prescription are still the legal bedrock of compounding.
2. The "Research Only" Trap: Products marketed online as "not for human consumption" or "research grade" bypass FDA manufacturing standards. If a patient takes these without adequate supervision, you could face vicarious liability.
3. Documentation is Your Shield: Ensure your charts reflect a clear medical necessity for the compounded peptide over commercially available alternatives. Research without an actual plan borders, if not crosses into, malpractice. Make sure you have all your documentation in place.
If you're unsure if your sourcing or consent forms meet current FDA expectations, now is the time to audit your peptide protocols.
Have you seen an uptick in patients asking for BPC-157? Message me to discuss the shift in the comments.
